Navigation Links
New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!

WESTON, Mass., Oct. 2 /PRNewswire/ -- Weston Medical Publishing today announced publication of the first issue of Journal of Neurodegeneration and Regeneration. (ISSN 1932-1481) This new peer-reviewed journal is designed to explore all aspects of neurodegeneration, neuroprotection and neuroregeneration including the molecular mechanisms, experimental approaches and their relevance in treating neurodegenerative disorders and neuroregenerative therapies.

When making the announcement, Publisher, Richard A. DeVito Jr. pointed out that while diagnosis may be the first step on the road of long term care for neurodegenerative patients, the pot of gold at the end of this difficult road will come from the challenging new frontier of neuroprotection and neuroregeneration research.

With the introduction of Journal of Neurodegeneration and Regeneration, (available online free of charge at until October 15th, 2008), the top neurospecialists worldwide will meet this challenge and bring to the medical community a long awaited exploration of the on-going research being conducted in this critical field.

Said DeVito, "The element of urgency couldn't be clearer. The numbers speak for themselves. In the United States alone, almost five million suffer from Alzheimer's disease; one million from Parkinson's disease; 400,000 from multiple sclerosis; and 30,000 from ALS. Worldwide, these four diseases account for more than 20 million patients."

"Further," he went on to say, "It is generally accepted that things are going to get worse before they get better. Aging greatly increases the risk of neurodegenerative disease and the average age of Americans and the worldwide populations are increasing. Today, over 37 million Americans alone are over the age of 65. Within the next 30 years this number is likely to double, putting more and more people at increased risk of neurodegenerative diseases."

"Research," DeVito noted, "will lead to better diagnosis, more effective treatments and, perhaps, cures for diseases like Alzheimer's, Parkinson's, multiple sclerosis, ALS and other diseases where few effective treatments and no cures are currently available."

The Journal of Neurodegeneration and Regeneration is guided by an international editorial review board of the foremost experts in the field under the leadership of co-Editors-in-Chief Dr. Philippe Taupin, PhD and Dr. Cathy Helgason, MD.

For manuscript submission or subscription information, visit the journal's Web page at or contact the publisher, Weston Medical Publishing LLC, at 781-899-2702.

Contact: Richard A. DeVito, Jr.

Weston Medical Publishing


SOURCE Weston Medical Publishing
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
3. Elsevier launches new journal: Stem Cell Research
4. Elsevier announces new journal on inflammatory bowel diseases
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
7. Good Clinical Practice Journal Awards: Winners Announced
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
10. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
11. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: